[ Aadi Bioscience raises $23M in Series A ]
Aadi Bioscience has raised $23 million in Series A funding.
Founded by Dr. Neil Desai, Aadi Bioscience is a clinical-stage biopharmaceutical company that develops mTOR inhibitor for the treatment of oncology and cardiovascular diseases.
The company will use the capital to drive the clinical programs for ABI-009, its targeted albumin-bound mTOR inhibitor.
|City||Pacific Palisades, California|
|Founder / CEO||Neil Desai|
|Investors||Star Summit Ventures|
|Helsinn Investment Fund|